Xenon Pharmaceuticals Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ian C. Mortimer
- Full Time Employees
- 364
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3650 Gilmore Way Burnaby BC Canada V5G 4W8
- IPO Date
- Nov 5, 2014
- CIK
- 0001582313
- Website
- xenon-pharma.com
- Similar Companies
- Business
- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company founded in 1996 and headquartered in Burnaby, British Columbia, Canada, with additional offices in Boston, Massachusetts, engages in the discovery, clinical development, and commercialization of novel therapeutics targeting neurological and psychiatric disorders through ion channel modulation. The company advances a differentiated pipeline led by its flagship product candidate azetukalner, a novel, potent, selective Kv7 potassium channel opener in multiple Phase 3 clinical trials for focal onset seizures (X-TOLE2, X-TOLE3), primary generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2, X-NOVA3), and bipolar depression (X-CEED); early-stage wholly-owned programs include XEN1120, a Kv7 potassium channel opener in Phase 1 for pain, and XEN1701, a Nav1.7 sodium channel inhibitor in Phase 1 for pain, alongside undisclosed preclinical Kv7 openers for epilepsy, pain, and psychiatry, Nav1.7 inhibitors for pain, and Nav1.1 sodium channel openers for Dravet syndrome. It also maintains a partnered program with Neurocrine Biosciences for NBI-921355 (formerly XEN901), a selective Nav1.2/1.6 sodium channel inhibitor in Phase 1 for epilepsy. Xenon serves patients with high unmet needs in epilepsy, depression, bipolar disorder, pain, and related neuropsychiatric conditions across North America and global clinical trial sites. Recent developments include completion of patient randomization in the Phase 3 X-TOLE2 trial for focal onset seizures with topline data expected in early 2026, ongoing recruitment in X-NOVA2/3 for major depressive disorder and X-CEED for bipolar depression, presentation of new long-term safety and efficacy data for azetukalner from the X-TOLE open-label extension at the American Epilepsy Society Annual Meeting in December 2025, and maintenance of a strong cash position of $555.3 million as of September 30, 2025, anticipated to fund operations into 2027 amid elevated R&D expenses for late-stage programs.
Company News
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
Xenon Stock Reaction Is Overblown: Analyst
Stock Futures Mixed After Thursday's Rebound
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript
Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
Xenon to Present at Wells Fargo Healthcare Conference